BACKGROUND: T-cell tolerance of allergic cutaneous contact sensitivity (CS) induced in mice by high doses of reactive hapten is mediated by suppressor cells that release antigen-specific suppressive nanovesicles. OBJECTIVE: We sought to determine the mechanism or mechanisms of immune suppression mediated by the nanovesicles. METHODS: T-cell tolerance was induced by means of intravenous injection of hapten conjugated to self-antigens of syngeneic erythrocytes and subsequent contact immunization with the same hapten. Lymph node and spleen cells from tolerized or control donors were harvested and cultured to produce a supernatant containing suppressive nanovesicles that were isolated from the tolerized mice for testing in active and adoptive cell-transfer models of CS. RESULTS: Tolerance was shown due to exosome-like nanovesicles in the supernatants of CD8(+) suppressor T cells that were not regulatory T cells. Antigen specificity of the suppressive nanovesicles was conferred by a surface coat of antibody light chains or possibly whole antibody, allowing targeted delivery of selected inhibitory microRNA (miRNA)-150 to CS effector T cells. Nanovesicles also inhibited CS in actively sensitized mice after systemic injection at the peak of the responses. The role of antibody and miRNA-150 was established by tolerizing either panimmunoglobulin-deficient JH(-/-) or miRNA-150(-/-) mice that produced nonsuppressive nanovesicles. These nanovesicles could be made suppressive by adding antigen-specific antibody light chains or miRNA-150, respectively. CONCLUSIONS: This is the first example of T-cell regulation through systemic transit of exosome-like nanovesicles delivering a chosen inhibitory miRNA to target effector T cells in an antigen-specific manner by a surface coating of antibody light chains.
BACKGROUND: T-cell tolerance of allergic cutaneous contact sensitivity (CS) induced in mice by high doses of reactive hapten is mediated by suppressor cells that release antigen-specific suppressive nanovesicles. OBJECTIVE: We sought to determine the mechanism or mechanisms of immune suppression mediated by the nanovesicles. METHODS: T-cell tolerance was induced by means of intravenous injection of hapten conjugated to self-antigens of syngeneic erythrocytes and subsequent contact immunization with the same hapten. Lymph node and spleen cells from tolerized or control donors were harvested and cultured to produce a supernatant containing suppressive nanovesicles that were isolated from the tolerized mice for testing in active and adoptive cell-transfer models of CS. RESULTS: Tolerance was shown due to exosome-like nanovesicles in the supernatants of CD8(+) suppressor T cells that were not regulatory T cells. Antigen specificity of the suppressive nanovesicles was conferred by a surface coat of antibody light chains or possibly whole antibody, allowing targeted delivery of selected inhibitory microRNA (miRNA)-150 to CS effector T cells. Nanovesicles also inhibited CS in actively sensitized mice after systemic injection at the peak of the responses. The role of antibody and miRNA-150 was established by tolerizing either panimmunoglobulin-deficient JH(-/-) or miRNA-150(-/-) mice that produced nonsuppressive nanovesicles. These nanovesicles could be made suppressive by adding antigen-specific antibody light chains or miRNA-150, respectively. CONCLUSIONS: This is the first example of T-cell regulation through systemic transit of exosome-like nanovesicles delivering a chosen inhibitory miRNA to target effector T cells in an antigen-specific manner by a surface coating of antibody light chains.
Authors: Maciej Juryńczyk; Agata Walczak; Anna Jurewicz; Dorota Jesionek-Kupnicka; Marian Szczepanik; Krzysztof Selmaj Journal: Ann Neurol Date: 2010-11 Impact factor: 10.422
Authors: Hong Jiang; Steve M Canfield; Mary P Gallagher; Hong H Jiang; Yihua Jiang; Zongyu Zheng; Leonard Chess Journal: J Clin Invest Date: 2010-09-27 Impact factor: 14.808
Authors: T Groot Kormelink; J Tekstra; R M Thurlings; M H J Boumans; K Vos; P P Tak; J W J Bijlsma; F P J G Lafeber; F A Redegeld; J A G van Roon Journal: Ann Rheum Dis Date: 2010-08-02 Impact factor: 19.103
Authors: David G Meckes; Kathy H Y Shair; Aron R Marquitz; Che-Pei Kung; Rachel H Edwards; Nancy Raab-Traub Journal: Proc Natl Acad Sci U S A Date: 2010-11-08 Impact factor: 11.205
Authors: Maria Eldh; Karin Ekström; Hadi Valadi; Margareta Sjöstrand; Bob Olsson; Margareta Jernås; Jan Lötvall Journal: PLoS One Date: 2010-12-17 Impact factor: 3.240
Authors: Silke Paust; Harvinder S Gill; Bao-Zhong Wang; Michael P Flynn; E Ashley Moseman; Balimkiz Senman; Marian Szczepanik; Amalio Telenti; Philip W Askenase; Richard W Compans; Ulrich H von Andrian Journal: Nat Immunol Date: 2010-10-24 Impact factor: 25.606
Authors: Kasper Bendix Johnsen; Johann Mar Gudbergsson; Martin Najbjerg Skov; Gunna Christiansen; Leonid Gurevich; Torben Moos; Meg Duroux Journal: Cytotechnology Date: 2016-02-08 Impact factor: 2.058